| Date | Title | Description |
| 05.03.2024 | Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting | - |
| 08.01.2024 | Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases | Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration of enrollment of NX-5948 in leukemia and lymphoma
Strategic collaborations in small molecule, targeted protein degradation with Gilead ... |
| 25.10.2023 | Developer delivers 120-square-foot life science innovation hub to The Woodlands | A new innovation hub mega campus has opened in The Woodlands.
The Alexandria Center for Advanced Technologies at The Woodlands comes courtesy of California-based Alexandria Real Estate Equities Inc. The campus is home to the first purpose-b... |
| 11.02.2022 | Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference | SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that
Arthur T. Sands, M.D., Ph.D., Nurix’s president and chi... |
| 28.01.2022 | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update | Advanced four wholly owned and internally developed programs into clinical development
Strengthened balance sheet with year-end cash and investments totaling $433 million
Anticipate multiple clinical milestones in 2022
SAN FRANCISCO, Jan. 2... |
| 28.01.2022 | Nurix Therapeutics : Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update - Form 8-K | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update
Advanced four wholly owned and internally developed programs into clinical development
Strengthened balance sheet with year-end... |
| 27.01.2022 | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update | Advanced four wholly owned and internally developed programs into clinical development
Strengthened balance sheet with year-end cash and investments totaling $433 million
Anticipate multiple clinical milestones in 2022
SAN FRANCISCO, Jan. 2... |
| 10.01.2022 | Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts | Nurix leads protein modulation field with four active clinical stage programs
Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform
SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nu... |
| 03.01.2022 | Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference | SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., president and chief execu... |
| 12.12.2021 | Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting | U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022
NX‑5948 crosses the blood‑brain barrier in preclinical models enabling potential dual development in oncology ... |
| 12.12.2021 | Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting | U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022
NX‑5948 crosses the blood‑brain barrier in preclinical models enabling potential dual development in oncology ... |
| 12.11.2021 | Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors | Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial
Phase 1 clinical trial initiation anticipated by year-end 2021
SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a bio... |
| 12.11.2021 | Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors | Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial
Phase 1 clinical trial initiation anticipated by year-end 2021
SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a bio... |
| 12.11.2021 | Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference | DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL
Michael T. Lotze, Nurix’s chief cellular therapy officer, is awarded Lifetime Achievem... |
| 12.11.2021 | Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference | DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL
Michael T. Lotze, Nurix’s chief cellular therapy officer, is awarded Lifetime Achievem... |
| 09.11.2021 | Nurix Therapeutics to Participate in Upcoming Investor Conferences | SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chi... |
| 27.10.2021 | Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies | Robust BTK target degradation achieved in all patients treated to date
Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127
These data represent the first proof of mechanism of targeted protein degradation in patie... |
| 27.10.2021 | Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies | Robust BTK target degradation achieved in all patients treated to date
Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127
These data represent the first proof of mechanism of targeted protein degradation in patie... |
| 26.10.2021 | Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit | Presentation to include initial pharmacokinetic and BTK degradation data
Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX)... |
| 21.10.2021 | Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit | SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s president and chief executive officer Arthur T.... |
| 14.10.2021 | Nurix Therapeutics : Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update | Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer
Expanded Board of Directors with experienced business leaders
Strong financial position with $465.4 million as of August 31, 2021
SAN FRANCISC... |
| 14.10.2021 | Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update | Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer
Expanded Board of Directors with experienced business leaders
Strong financial position with $465.4 million as of August 31, 2021
SAN FRANCISC... |
| 21.06.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development | SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operat... |
| 02.06.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease | Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity
Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress
SAN FRANCISCO, June ... |
| 21.05.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress | SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data from its NX-5948 program will be presen... |
| 07.04.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference | SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive ... |
| 16.03.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers | Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma
Program is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative
SAN FRANCISCO, March 16, 20... |
| 16.03.2021 | Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers | Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma
Program is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative
SAN FRANCISCO, March 16, 20... |
| 09.03.2021 | Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences | SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive off... |
